References
- Abdel-Azeem, H.A., et al., 2019. Diagnostic role of cyclin D1 as a new marker for early diagnosis of breast cancer. Journal of current medical research and practice, 4 (1), 6–10.
- Ali, H.Q., Mahdi, N.K., and Al-Jowher, M.H., 2013. The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer. Journal of Pakistan medical association, 63 (9), 1138–1141.
- Amodio, N., et al., 2015. MiR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget, 6 (15), 12837–12861.
- Blandin, A.F., et al., 2015. β1 integrins as therapeutic targets to disrupt hallmarks of cancer. Frontiers in pharmacology, 6, 279.
- Bray, F., et al., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68 (6), 394–424.
- Castro-Sanchez, L., et al., 2011. Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells. Clinical & experimental metastasis, 28 (5), 463–477.
- Chen, L., et al., 2016. MiR-335 inhibits cell proliferation, migration and invasion in HeLa cervical cancer cells. International journal of clinical and experimental pathology, 9 (10), 10351–10362.
- Chou, J., et al., 2013. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nature cell biology, 15 (2), 201–213.
- Das, K., et al., 2018. Matrix metalloproteinase-2: a key regulator in coagulation proteases mediated human breast cancer progression through autocrine signaling. Biomedicine & pharmacotherapy, 105, 395–406.
- Dong, Y., et al., 2018. MicroRNA-335 suppresses the proliferation, migration, and invasion of breast cancer cells by targeting EphA4. Molecular and cellular biochemistry, 439 (1–2), 95–104.
- El-Shorbagy, H.M., Mahmoud, N.H., and Sabet, S., 2017. Association of vitamin D receptor gene polymorphisms with breast cancer risk in an Egyptian population. Tumor biology, 39 (10), 101042831772773.
- Fang, J.H., et al., 2011. MicroRNA‐29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology, 54 (5), 1729–1740.
- Filipów, S. and Łaczmański, Ł., 2019. Blood circulating miRNAs as cancer biomarkers for diagnosis and surgical treatment response. Frontiers in genetics, 10, 169.
- Gao, Y., et al., 2015. MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met. Tumor biology, 36 (4), 2875–2883.
- Ghasabeh, H.R. and Keyhanian, S., 2013. Relationship between tumor markers CEA and CA15-3 and recurrence breast cancer. Journal of paramedical science, 4 (1), 16–20.
- Greene, F.L. and Sobin, L.H., 2008. The staging of cancer: a retrospective and prospective appraisal. CA: a cancer journal for clinicians, 58 (3), 180–190.
- Hafez, M.M., et al., 2012. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pacific journal of cancer prevention, 13 (2), 591–598.
- Hamdi, K., et al., 2014. MiRNAs in Sera of Tunisian patients discriminate between inflammatory breast cancer and non-inflammatory breast cancer. SpringerPlus, 3 (1), 636.
- Han, H.S., et al., 2014. MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6. FEBS letters, 588 (20), 3744–3750.
- Heyn, H., et al., 2011. MicroRNA miR‐335 is crucial for the BRCA1 regulatory cascade in breast cancer development. International journal of cancer, 129 (12), 2797–2806.
- Hirko, K.A., et al., 2013. Trends in breast cancer incidence rates by age and stage at diagnosis in gharbiah, Egypt, over 10 years (1999–2008. Journal of cancer epidemiology, 2013, 1–7.
- Hsu, S.M., Raine, L., and Fanger, H., 1981. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. American journal of clinical pathology, 75 (5), 734–738.
- Hwang, H.W., Wentzel, E.A., and Mendell, J.T., 2007. A hexanucleotide element directs microRNA nuclear import. Science, 315 (5808), 97–100.
- Ibrahim, A.S., et al., 2014. Cancer incidence in Egypt: results of the national population-based cancer registry program. Journal of cancer epidemiology, 2014, 1–18.
- Kim, S.H., et al., 2008. Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer. Acta oncologica, 47 (8), 1531–1538.
- Kittelmann, S. and McGregor, A.P., 2019. Modulation and evolution of animal development through microRNA regulation of gene expression. Genes, 10 (4), 321.
- Kriegel, A.J., et al., 2012. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiological genomics, 44 (4), 237–244.
- Li, H., et al., 2015. MicroRNA-29a inhibits cell migration and invasion by targeting Roundabout 1 in breast cancer cells. Molecular medicine reports, 12 (2), 3121–3126.
- Liu, X., et al., 2015. MicroRNA-29a inhibits cell migration and invasion via targeting Roundabout homolog 1 in gastric cancer cells. Molecular medicine reports, 12 (3), 3944–3950.
- Livak, K.J. and Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC (T) method. Methods, 25 (4), 402–408.
- Lu, L., et al., 2014. MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomedicine & pharmacotherapy, 68 (1), 13–19.
- Marić, P., et al., 2011. Tumor markers in breast cancer–evaluation of their clinical usefulness. Collegium antropologicum, 35 (1), 241–247.
- Ni, Y.J., Lu, J., and Zhou, H.M., 2019. Propofol suppresses proliferation, migration and invasion of gastric cancer cells via regulating miR-29/MMP-2 axis. European review for medical and pharmacological sciences., 23 (8606), e15.
- Nishikawa, R., et al., 2015. Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. FEBS letters, 589 (16), 2136–2145.
- Pei, Y.F., Lei, Y., and Liu, X.Q., 2016. MiR-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1. Biochimica et biophysica acta, 1862 (11), 2177–2185.
- Png, K.J., et al., 2011. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes & development, 25 (3), 226–231.
- Qi, Y., et al., 2017. Prognostic value of the Micro RNA‐29 family in multiple human cancers: a meta‐analysis and systematic review. Clinical and experimental pharmacology and physiology, 44 (4), 441–454.
- Robbins, P., et al., 1995. Histological grading of breast carcinomas: a study of interobserver agreement. Human pathology, 26 (8), 873–879.
- Rojas, F., et al., 2015. The oncogenic response to miR-335 is associated with cell surface expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) activity. PLoS One, 10 (7), e0132026.
- Sareyeldin, R.M., et al., 2019. Gene expression and miRNAs profiling: function and regulation in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Cancers, 11 (5), 646.
- Shah, F.D., et al., 2009. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian journal of cancer, 46 (3), 194–202.
- Shi, Y., et al., 2017. Propoxur enhances MMP-2 expression and the corresponding invasion of human breast cancer cells via the ERK/Nrf2 signaling pathway. Oncotarget, 8 (50), 87107–87123.
- Swellam, M., et al., 2019. Clinical significance of blood‐based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: comparative to conventional tumor markers. Journal of cellular biochemistry, 120 (8), 12321–12330.
- Tang, W., et al., 2014. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. British journal of cancer, 110 (2), 450–458.
- Tavazoie, S.F., et al., 2008. Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451 (7175), 147–152.
- Thriveni, K., et al., 2013. Diagnostic significance of CA15-3 with combination of HER-2/neu values at 85th percentiles in breast cancer. Indian journal of clinical biochemistry, 28 (2), 136–140.
- Trehoux, S., et al., 2015. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochimica et biophysica acta, 1853 (10), 2392–2403.
- Valastyan, S., et al., 2009. RETRACTED: a pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell, 137 (6), 1032–1046.
- Wu, Q., et al., 2011. Next-generation sequencing of microRNAs for breast cancer detection. Journal of biomedicine and biotechnology, 2011, 1–7.
- Wu, Z., et al., 2013. The inhibitory role of Mir-29 in growth of breast cancer cells. Journal of experimental & clinical cancer research, 32 (1), 98–98.
- Zhao, Z., et al., 2015. Reduced miR-29a-3p expression is linked to the cell proliferation and cell migration in gastric cancer. World journal of surgical oncology, 13 (1), 101.
- Zheng, J., et al., 2013. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepatogastroenterology, 60 (123), 549–552.
- Zhong, Y., et al., 2018. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert opinion on drug discovery, 13 (1), 75–87.
- Zou, Y., et al., 2015. MiR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients. Carcinogenesis, 36 (6), 676–684.
- Zweig, M.H. and Campbell, G., 1993. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical chemistry, 39 (4), 561–577.